Answers are grounded in this paper and cite their sources.
Summary Up to a third of patients with schizophrenia develop treatment resistance. Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilised in this population. Possible reasons include clinicians' lack of experience with the drug and negative attitudes towards it. African-Caribbean patients are less likely to be treated with clozapine compared with their White counterparts and more likely to have treatment discontinued due to perceived risk of agranulocytosis. This paper discusses the current evidence relating to the underuse of clozapine and factors responsible for this.
No takes yet. Share an insight, caveat, or question.
Mistry et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: